PT  - JOURNAL ARTICLE
AU  - STENDEL, RUEDIGER
AU  - PICHT, THOMAS
AU  - SCHILLING, ANDREAS
AU  - HEIDENREICH, JENS
AU  - LODDENKEMPER, CHRISTOPH
AU  - JÄNISCH, WERNER
AU  - BROCK, MARIO
TI  - Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience
DP  - 2004 Mar 01
TA  - Anticancer Research
PG  - 1143--1148
VI  - 24
IP  - 2C
4099  - http://ar.iiarjournals.org/content/24/2C/1143.short
4100  - http://ar.iiarjournals.org/content/24/2C/1143.full
SO  - Anticancer Res2004 Mar 01; 24
AB  - Background: Despite progress in diagnosis and therapy, the prognosis of patients with glioblastoma remains poor. Recently it has been found that the antibacterial agent taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of programmed cell death. This paper reports on intravenous taurolidine treatment in two patients with a progressive glioblastoma despite conventional therapy. Patients and Methods: Two male patients with histopathologically diagnosed glioblastoma were included. The tumors were progressive despite conventional therapy. Intravenous taurolidine treatment was initiated. Results: The neurological condition and quality of life improved in both patients such that they could be discharged for further outpatient treatment. Follow-up demonstrated partial remission of the tumor in both patients. However, both patients died about 4 months following the start of taurolidine treatment, from pneumonia and acute thrombembolism, respectively. Conclusion: Both patients achieved a transient, marked improvement in quality of life and partial tumor remission. There was a clear response to the taurolidine treatment. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved